Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03827668 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction Study Between PF-06650833 AND PF-06651600 Following Multiple Doses IN Healthy Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03827668 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT03827668, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential pharmacokinetic (PK) drug-drug interaction (DDI) between PF-06650833 and PF-06651600 in healthy adult participants.
Interventions
- DRUG PF-06650833 alone
- DRUG PF-06651600 alone
- DRUG PF-06650833 together with PF-06651600
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2019-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03827668
The ClinicalTrials.gov registry entry for NCT03827668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-06650833 alone is the first listed.
NCT03827668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03827668 about?
NCT03827668 is a clinical study titled "A Drug-drug Interaction Study Between PF-06650833 AND PF-06651600 Following Multiple Doses IN Healthy Participants". The purpose of this study is to evaluate the potential pharmacokinetic (PK) drug-drug interaction (DDI) between PF-06650833 and PF-06651600 in healthy adult participants.
What is the current status of trial NCT03827668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-02-07. Estimated completion is 2019-04-29.
What interventions are being tested in trial NCT03827668?
The interventions under investigation include: PF-06650833 alone (DRUG), PF-06651600 alone (DRUG), PF-06650833 together with PF-06651600 (DRUG).
Who is sponsoring clinical trial NCT03827668?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.